Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT05230901

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
University Medical Center Goettingen (from the registry)
Registry
  • NCT NCT05230901
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05230901. Randomized; no masking; primary purpose treatment. Start 2022-02-23 (actual); primary completion 2025-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden
Acronym
Reduce-MFA
Condition
Aortic Stenosis, Severe
Intervention (Other)
Standard of Care
Intervention (Drug)
Spironolactone 25mg
Intervention (Drug)
Dihydralazine
Lead sponsor
University Medical Center Goettingen (class: other)

Record details

Record id
cardio:ct-nct05230901
Content hash
3a9ae49d55ef33d8b3efe060034a5e3f6d115b81f9738381099a22bde6a9dbdc